Semin Neurol 2020; 40(04): 420-429
DOI: 10.1055/s-0040-1713631
Review Article

Genetics of Chronic Traumatic Encephalopathy

Bobak Abdolmohammadi
1   Boston University Alzheimer’s Disease Center, Boston University School of Medicine, Boston, MA
2   Boston University Chronic Traumatic Encephalopathy Center, Boston University School of Medicine, Boston, MA
3   Department of Neurology, Boston University School of Medicine, Boston, MA
Alicia Dupre
1   Boston University Alzheimer’s Disease Center, Boston University School of Medicine, Boston, MA
2   Boston University Chronic Traumatic Encephalopathy Center, Boston University School of Medicine, Boston, MA
3   Department of Neurology, Boston University School of Medicine, Boston, MA
Laney Evers
1   Boston University Alzheimer’s Disease Center, Boston University School of Medicine, Boston, MA
2   Boston University Chronic Traumatic Encephalopathy Center, Boston University School of Medicine, Boston, MA
3   Department of Neurology, Boston University School of Medicine, Boston, MA
Jesse Mez
1   Boston University Alzheimer’s Disease Center, Boston University School of Medicine, Boston, MA
2   Boston University Chronic Traumatic Encephalopathy Center, Boston University School of Medicine, Boston, MA
3   Department of Neurology, Boston University School of Medicine, Boston, MA
› Author Affiliations


Although chronic traumatic encephalopathy (CTE) garners substantial attention in the media and there have been marked scientific advances in the last few years, much remains unclear about the role of genetic risk in CTE. Two athletes with comparable contact-sport exposure may have varying amounts of CTE neuropathology, suggesting that other factors, including genetics, may contribute to CTE risk and severity. In this review, we explore reasons why genetics may be important for CTE, concepts in genetic study design for CTE (including choosing controls, endophenotypes, gene by environment interaction, and epigenetics), implicated genes in CTE (including APOE, MAPT, and TMEM106B), and whether predictive genetic testing for CTE should be considered.

Publication History

Article published online:
26 July 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

  • References

  • 1 Nelson MR, Tipney H, Painter JL. , et al. The support of human genetic evidence for approved drug indications. Nat Genet 2015; 47 (08) 856-860
  • 2 Janssens ACJ, van Duijn CM. Genome-based prediction of common diseases: methodological considerations for future research. Genome Med 2009; 1 (02) 20
  • 3 Beason-Held LL, Goh JO, An Y. , et al. Changes in brain function occur years before the onset of cognitive impairment. J Neurosci 2013; 33 (46) 18008-18014
  • 4 Jonsson T, Stefansson H, Steinberg S. , et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368 (02) 107-116
  • 5 Harold D, Abraham R, Hollingworth P. , et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41 (10) 1088-1093
  • 6 Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96 (06) 434-442
  • 7 Reitz C, Mayeux R. Endophenotypes in normal brain morphology and Alzheimer's disease: a review. Neuroscience 2009; 164 (01) 174-190
  • 8 De Jager PL, Bennett DA. An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome. JAMA Neurol 2013; 70 (06) 719-726
  • 9 Thomas D. Gene--environment-wide association studies: emerging approaches. Nat Rev Genet 2010; 11 (04) 259-272
  • 10 Surtees R, Blau N. The neurochemistry of phenylketonuria. Eur J Pediatr 2000; 159 (Suppl. 02) S109-S113
  • 11 Koch R, Burton B, Hoganson G. , et al. Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis 2002; 25 (05) 333-346
  • 12 Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33: 245-254
  • 13 McGowan PO, Sasaki A, D'Alessio AC. , et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009; 12 (03) 342-348
  • 14 Tammen SA, Friso S, Choi S-W. Epigenetics: the link between nature and nurture. Mol Aspects Med 2013; 34 (04) 753-764
  • 15 Corder EH, Saunders AM, Strittmatter WJ. , et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261 (5123): 921-923
  • 16 Farrer LA, Cupples LA, Haines JL. , et al; APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997; 278 (16) 1349-1356
  • 17 Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 11 (04) 575-580
  • 18 Shi Y, Yamada K, Liddelow SA. Alzheimer's Disease Neuroimaging Initiative. , et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 2017; 549 (7673): 523-527
  • 19 Tzioras M, Davies C, Newman A, Jackson R, Spires-Jones T. Invited review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease. Neuropathol Appl Neurobiol 2019; 45 (04) 327-346
  • 20 Rubino E, Vacca A, Govone F, De Martino P, Pinessi L, Rainero I. Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: a meta-analysis. Alzheimers Dement 2013; 9 (06) 706-713
  • 21 Dickson DW, Heckman MG, Murray ME. , et al. APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology 2018; 91 (12) e1182-e1195
  • 22 Mayeux R, Ottman R, Maestre G. , et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995; 45 (3, Pt 1): 555-557
  • 23 Guo Z, Cupples LA, Kurz A. , et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000; 54 (06) 1316-1323
  • 24 Jellinger KA, Paulus W, Wrocklage C, Litvan I. Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease. 2001; 8 (06) 707-710
  • 25 Crane PK, Gibbons LE, Dams-O'Connor K. , et al. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol 2016; 73 (09) 1062-1069
  • 26 Uzan M, Tanriverdi T, Baykara O. , et al. Association between interleukin-1 beta (IL-1beta) gene polymorphism and outcome after head injury: an early report. Acta Neurochir (Wien) 2005; 147 (07) 715-720 , discussion 720
  • 27 Jordan BD, Relkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 1997; 278 (02) 136-140
  • 28 Kutner KC, Erlanger DM, Tsai J, Jordan B, Relkin NR. Lower cognitive performance of older football players possessing apolipoprotein E epsilon4. Neurosurgery 2000; 47 (03) 651-657 , discussion 657–658
  • 29 McKee AC, Stern RA, Nowinski CJ. , et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013; 136 (Pt 1): 43-64
  • 30 Stern RA, Daneshvar DH, Baugh CM. , et al. Clinical presentation of chronic traumatic encephalopathy. Neurology 2013; 81 (13) 1122-1129
  • 31 Bieniek KF, Ross OA, Cormier KA. , et al. Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol 2015; 130 (06) 877-889
  • 32 Murray ME, Kouri N, Lin W-L, Jack Jr CR, Dickson DW, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther 2014; 6 (01) 1
  • 33 Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging 2001; 22 (01) 89-107
  • 34 Pittman AM, Myers AJ, Abou-Sleiman P. , et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 2005; 42 (11) 837-846
  • 35 Santa-Maria I, Haggiagi A, Liu X. , et al. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol 2012; 124 (05) 693-704
  • 36 Baker M, Litvan I, Houlden H. , et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999; 8 (04) 711-715
  • 37 Rademakers R, Melquist S, Cruts M. , et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005; 14 (21) 3281-3292
  • 38 Myers AJ, Kaleem M, Marlowe L. , et al. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet 2005; 14 (16) 2399-2404
  • 39 Myers AJ, Pittman AM, Zhao AS. , et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 2007; 25 (03) 561-570
  • 40 Brady OA, Zheng Y, Murphy K, Huang M, Hu F. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet 2013; 22 (04) 685-695
  • 41 Suzuki H, Matsuoka M. The lysosomal trafficking transmembrane Protein 106B Is linked to cell death. J Biol Chem 2016; 291 (41) 21448-21460
  • 42 Van Deerlin VM, Sleiman PMA, Martinez-Lage M. , et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010; 42 (03) 234-239
  • 43 Vass R, Ashbridge E, Geser F. , et al. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol 2011; 121 (03) 373-380
  • 44 Jun G, Ibrahim-Verbaas CA, Vronskaya M. , et al. IGAP Consortium. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 2016; 21 (01) 108-117
  • 45 Nelson PT, Wang W-X, Partch AB. , et al. Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology. J Neuropathol Exp Neurol 2015; 74 (01) 75-84
  • 46 McKee AC, Gavett BE, Stern RA. , et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010; 69 (09) 918-929
  • 47 Mez J, Daneshvar DH, Kiernan PT. , et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of american football. JAMA 2017; 318 (04) 360-370
  • 48 Rhinn H, Abeliovich A. Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell Syst 2017; 4 (04) 404-415.e5
  • 49 Cherry JD, Tripodis Y, Alvarez VE. , et al. Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol Commun 2016; 4 (01) 112
  • 50 Cherry JD, Mez J, Crary JF. , et al. Variation in TMEM106B in chronic traumatic encephalopathy. Acta Neuropathol Commun 2018; 6 (01) 115
  • 51 Roberts JS, Uhlmann WR. Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. Prog Neurobiol 2013; 110: 89-101
  • 52 Committee on Bioethics; Committee on Genetics, and; American College Of Medical Genetics and; Genomics Social; Ethical; Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Pediatrics 2013; 131 (03) 620-622
  • 53 SFIA. 2018 Sports, fitness, and leisure activities topline participation report. Available at: . Accessed January 11, 2019
  • 54 Winkler EA, Yue JK, Ferguson AR. , et al. TRACK-TBI Investigators. COMT Val158Met polymorphism is associated with post-traumatic stress disorder and functional outcome following mild traumatic brain injury. J Clin Neurosci 2017; 35: 109-116
  • 55 Nielson JL, Cooper SR, Yue JK. , et al. TRACK-TBI Investigators. Uncovering precision phenotype-biomarker associations in traumatic brain injury using topological data analysis. PLoS One 2017; 12 (03) e0169490
  • 56 Failla MD, Myrga JM, Ricker JH, Dixon CE, Conley YP, Wagner AK. Posttraumatic brain injury cognitive performance is moderated by variation within ANKK1 and DRD2 genes. J Head Trauma Rehabil 2015; 30 (06) E54-E66
  • 57 Tanriverdi T, Uzan M, Sanus GZ. , et al. Lack of association between the IL1A gene (-889) polymorphism and outcome after head injury. Surg Neurol 2006; 65 (01) 7-10 , discussion 10
  • 58 Diamond ML, Ritter AC, Failla MD. , et al. IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia 2014; 55 (07) 1109-1119
  • 59 Hadjigeorgiou GM, Paterakis K, Dardiotis E. , et al. IL-1RN and IL-1B gene polymorphisms and cerebral hemorrhagic events after traumatic brain injury. Neurology 2005; 65 (07) 1077-1082
  • 60 Waters RJ, Murray GD, Teasdale GM. , et al. Cytokine gene polymorphisms and outcome after traumatic brain injury. J Neurotrauma 2013; 30 (20) 1710-1716
  • 61 Failla MD, Kumar RG, Peitzman AB, Conley YP, Ferrell RE, Wagner AK. Variation in the BDNF gene interacts with age to predict mortality in a prospective, longitudinal cohort with severe TBI. Neurorehabil Neural Repair 2015; 29 (03) 234-246
  • 62 Failla MD, Conley YP, Wagner AK. Brain-derived neurotrophic factor (BDNF) in traumatic brain injury-related mortality: interrelationships between genetics and acute systemic and central nervous system BDNF profiles. Neurorehabil Neural Repair 2016; 30 (01) 83-93
  • 63 Munoz MJ, Kumar RG, Oh B-M. , et al. Cerebrospinal fluid cortisol mediates brain-derived neurotrophic factor relationships to mortality after severe TBI: a prospective cohort study. Front Mol Neurosci 2017; 10: 44
  • 64 Hoh NZ, Wagner AK, Alexander SA. , et al. BCL2 genotypes: functional and neurobehavioral outcomes after severe traumatic brain injury. J Neurotrauma 2010; 27 (08) 1413-1427
  • 65 Bulstrode H, Nicoll JAR, Hudson G, Chinnery PF, Di Pietro V, Belli A. Mitochondrial DNA and traumatic brain injury. Ann Neurol 2014; 75 (02) 186-195
  • 66 Conley YP, Okonkwo DO, Deslouches S. , et al. Mitochondrial polymorphisms impact outcomes after severe traumatic brain injury. J Neurotrauma 2014; 31 (01) 34-41
  • 67 Martínez-Lucas P, Moreno-Cuesta J, García-Olmo DC. , et al. Relationship between the Arg72Pro polymorphism of p53 and outcome for patients with traumatic brain injury. Intensive Care Med 2005; 31 (09) 1168-1173
  • 68 Dardiotis E, Paterakis K, Siokas V. , et al. Effect of angiotensin-converting enzyme tag single nucleotide polymorphisms on the outcome of patients with traumatic brain injury. Pharmacogenet Genomics 2015; 25 (10) 485-490
  • 69 Chuang P-Y, Conley YP, Poloyac SM. , et al. Neuroglobin genetic polymorphisms and their relationship to functional outcomes after traumatic brain injury. J Neurotrauma 2010; 27 (06) 999-1006
  • 70 Wang ZL, Xu DS, Wang YX, Qin H, Geng D. Effect of single nucleotide polymorphisms in the ATP-binding cassette B1 gene on the clinical outcome of traumatic brain injury. Genet Mol Res 2015; 14 (03) 10948-10953
  • 71 Dardiotis E, Paterakis K, Tsivgoulis G. , et al. AQP4 tag single nucleotide polymorphisms in patients with traumatic brain injury. J Neurotrauma 2014; 31 (23) 1920-1926
  • 72 Garringer JA, Niyonkuru C, McCullough EH. , et al. Impact of aromatase genetic variation on hormone levels and global outcome after severe TBI. J Neurotrauma 2013; 30 (16) 1415-1425
  • 73 Sarnaik AA, Conley YP, Okonkwo DO. , et al. Influence of PARP-1 polymorphisms in patients after traumatic brain injury. J Neurotrauma 2010; 27 (03) 465-471
  • 74 Dalla Libera AL, Regner A, de Paoli J, Centenaro L, Martins TT, Simon D. IL-6 polymorphism associated with fatal outcome in patients with severe traumatic brain injury. Brain Inj 2011; 25 (04) 365-369
  • 75 Sinha S, Mansoori N, Mukhopadhyay A, Sharma B. Effect of IL-6-174 G/C polymorphism in predicting disability and functional outcome in patients with severe Traumatic Brain Injury (STBI). J Neurosurgery 2015; 112: 673
  • 76 Markos SM, Failla MD, Ritter AC. , et al. Genetic variation in the vesicular monoamine transporter: preliminary associations with cognitive outcomes after severe traumatic brain injury. J Head Trauma Rehabil 2017; 32 (02) E24-E34
  • 77 Myrga JM, Failla MD, Ricker JH. , et al. A dopamine pathway gene risk score for cognitive recovery following traumatic brain injury: methodological considerations, preliminary findings, and interactions with sex. J Head Trauma Rehabil 2016; 31 (05) E15-E29
  • 78 Zhou W, Xu D, Peng X, Zhang Q, Jia J, Crutcher KA. Meta-analysis of APOE4 allele and outcome after traumatic brain injury. J Neurotrauma 2008; 25 (04) 279-290
  • 79 Zeng S, Jiang JX, Xu MH. , et al. Prognostic value of apolipoprotein E epsilon4 allele in patients with traumatic brain injury: a meta-analysis and meta-regression. Genet Test Mol Biomarkers 2014; 18 (03) 202-210
  • 80 Lawrence DW, Comprec P, Hutchinson MD, Sharma G. The role of apolipoprotein E epsilon-4 allele on outcome following traumatic brain injury: a systematic review. Brain Inj 2015; 29 (09) 1018-1031
  • 81 McFadyen CA, Zeiler FA, Newcombe V. , et al. Apolipoprotein E4 Polymorphism and Outcomes from Traumatic Brain Injury: A Living Systematic Review and Meta-Analysis. J Neurotrauma 2019; DOI: 10.1089/neu.2018.6052.
  • 82 Lanoiselée H-M, Nicolas G, Wallon D. , et al; collaborators of the CNR-MAJ project. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med 2017; 14 (03) e1002270
  • 83 Lambert JC, Ibrahim-Verbaas CA, Harold D. , et al; European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45 (12) 1452-1458
  • 84 Kunkle BW, Grenier-Boley B, Sims R. , et al. Meta-analysis of genetic association with diagnosed Alzheimer's disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing. bioRxiv 2018 ;294629(April) Doi:
  • 85 White CC, Yang H-S, Yu L. , et al. Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. PLoS Med 2017; 14 (04) e1002287
  • 86 Jun GR, Chung J, Mez J. , et al. Alzheimer's Disease Genetics Consortium. Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 2017; 13 (07) 727-738
  • 87 Liu JZ, Erlich Y, Pickrell JK. Case-control association mapping by proxy using family history of disease. Nat Genet 2017; 49 (03) 325-331
  • 88 Guerreiro R, Wojtas A, Bras J. , et al. Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368 (02) 117-127
  • 89 Bis JC, Jian X, Kunkle BW. Alzheimer's Disease Sequencing Project. , et al. Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. Mol Psychiatry 2018; (e-pub ahead of print) DOI: 10.1038/s41380-018-0112-7.
  • 90 Mez J, Chung J, Jun G. , et al. Alzheimer's Disease Genetics Consortium. Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. Alzheimers Dement 2017; 13 (02) 119-129
  • 91 Logue MW, Schu M, Vardarajan BN. , et al. Alzheimer Disease Genetics Consortium; Alzheimer Disease Genetics Consortium. Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. Alzheimers Dement 2014; 10 (06) 609-618.e11
  • 92 Ruiz A, Heilmann S, Becker T. , et al. IGAP. Follow-up of loci from the International Genomics of Alzheimer's Disease Project identifies TRIP4 as a novel susceptibility gene. Transl Psychiatry 2014; 4 (02) e358
  • 93 Jakobsdottir J, van der Lee SJ, Bis JC. , et al. Cohorts for Heart and Aging Research in Genomic Epidemiology consortium; Alzheimer's Disease Genetic Consortium; Genetic and Environmental Risk in Alzheimer's Disease consortium. Rare functional variant in TM2D3 is associated with late-onset Alzheimer's disease. PLoS Genet 2016; 12 (10) e1006327
  • 94 Sims R, van der Lee SJ, Naj AC. , et al. ARUK Consortium; GERAD/PERADES, CHARGE, ADGC, EADI. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 2017; 49 (09) 1373-1384
  • 95 Jonsson T, Atwal JK, Steinberg S. , et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012; 488 (7409): 96-99
  • 96 Hutton M, Lendon CL, Rizzu P. , et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393 (6686): 702-705
  • 97 Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 2015; 41 (01) 24-46
  • 98 Höglinger GU, Melhem NM, Dickson DW. , et al. PSP Genetics Study Group. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43 (07) 699-705
  • 99 Zhao N, Liu C-C, Van Ingelgom AJ. , et al. APOE ε2 is associated with increased tau pathology in primary tauopathy. Nat Commun 2018; 9 (01) 4388
  • 100 Chen JA, Chen Z, Won H. , et al. Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Mol Neurodegener 2018; 13 (01) 41
  • 101 Sanchez-Contreras MY, Kouri N, Cook CN. , et al. Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener 2018; 13 (01) 37
  • 102 Jabbari E, Woodside J, Tan MMX. , et al. Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Ann Neurol 2018; 84 (04) 485-496
  • 103 Cousar JL, Conley YP, Willyerd FA. , et al. Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury. Neurocrit Care 2013; 19 (02) 192-198
  • 104 Zeiler FA, McFadyen C, Newcombe VFJ. , et al. Genetic influences on patient-oriented outcomes in traumatic brain injury: a living systematic review of non-apolipoprotein E single-nucleotide polymorphisms. J Neurotrauma 2019; DOI: 10.1089/neu.2017.5583.
  • 105 Osier ND, Bales JW, Pugh B. , et al. Variation in PPP3CC genotype is associated with long-term recovery after severe brain injury. J Neurotrauma 2017; 34 (01) 86-96